Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBITDA (2019 - 2025)

Allogene Therapeutics' EBITDA history spans 7 years, with the latest figure at -$41.1 million for Q3 2025.

  • For Q3 2025, EBITDA rose 37.08% year-over-year to -$41.1 million; the TTM value through Sep 2025 reached -$211.9 million, up 24.54%, while the annual FY2024 figure was -$256.7 million, 19.34% up from the prior year.
  • EBITDA for Q3 2025 was -$41.1 million at Allogene Therapeutics, up from -$51.0 million in the prior quarter.
  • Across five years, EBITDA topped out at -$2.1 million in Q4 2021 and bottomed at -$96.0 million in Q1 2023.
  • The 5-year median for EBITDA is -$66.2 million (2024), against an average of -$65.9 million.
  • The largest annual shift saw EBITDA soared 98.46% in 2021 before it plummeted 4043.64% in 2022.
  • A 5-year view of EBITDA shows it stood at -$2.1 million in 2021, then tumbled by 4043.64% to -$86.3 million in 2022, then increased by 2.31% to -$84.3 million in 2023, then increased by 28.62% to -$60.2 million in 2024, then skyrocketed by 31.68% to -$41.1 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's EBITDA are -$41.1 million (Q3 2025), -$51.0 million (Q2 2025), and -$59.6 million (Q1 2025).